FAM193A

Across TCGA pan-cancer cohorts, FAM193A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM193A data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM193A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FAM193A expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where FAM193A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	1.000	0.339	<.001	11	view →
UCEC	OS	Median	II,III,IV	1.000	0.647	.017	8	view →
PDAC	DFS	Median	III,IV	0.634	0.799	.049	2	view →
CCRCC	DFS	Median	All	0.586	0.914	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM193A–LUAD (OS)

Open the LUAD breakdown →